🚀 VC round data is live in beta, check it out!
Capricor Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Capricor Therapeutics and similar public comparables like Recursion Pharmaceuticals, Amylyx Pharmaceuticals, Pharma Mar, Hugel and more.
Capricor Therapeutics Overview
About Capricor Therapeutics
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Founded
2005
HQ
Employees
160
Website
Sectors
Financials (LTM)
EV
$2B
Capricor Therapeutics Financials
Capricor Therapeutics reported last 12-month revenue of $44M and negative EBITDA of ($113M).
In the same LTM period, Capricor Therapeutics generated $43M in gross profit, ($113M) in EBITDA losses, and had net loss of ($68M).
Revenue (LTM)
Capricor Therapeutics P&L
In the most recent fiscal year, Capricor Therapeutics reported revenue of — and EBITDA of ($100M).
Capricor Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $44M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $43M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($113M) | XXX | ($100M) | XXX | XXX | XXX |
| EBITDA Margin | (256%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (173%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($68M) | XXX | ($105M) | XXX | XXX | XXX |
| Net Margin | (153%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Capricor Therapeutics Stock Performance
Capricor Therapeutics has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Capricor Therapeutics' stock price is $34.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.3% | XXX | XXX | XXX | $-1.82 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCapricor Therapeutics Valuation Multiples
Capricor Therapeutics trades at 38.4x EV/Revenue multiple, and (15.0x) EV/EBITDA.
EV / Revenue (LTM)
Capricor Therapeutics Financial Valuation Multiples
As of April 18, 2026, Capricor Therapeutics has market cap of $2B and EV of $2B.
Equity research analysts estimate Capricor Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Capricor Therapeutics has a P/E ratio of (29.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 38.4x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (15.0x) | XXX | (17.0x) | XXX | XXX | XXX |
| EV/EBIT | (22.3x) | XXX | (15.8x) | XXX | XXX | XXX |
| EV/Gross Profit | 39.2x | XXX | — | XXX | XXX | XXX |
| P/E | (29.6x) | XXX | (19.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (20.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Capricor Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Capricor Therapeutics Margins & Growth Rates
Capricor Therapeutics' revenue in the last 12 month grew by 216%.
Capricor Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.
Capricor Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 216% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (256%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 58% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 188% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Capricor Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Capricor Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Recursion Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Amylyx Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Mar | XXX | XXX | XXX | XXX | XXX | XXX |
| Hugel | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Wolwo Bio-Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Capricor Therapeutics M&A Activity
Capricor Therapeutics acquired XXX companies to date.
Last acquisition by Capricor Therapeutics was on XXXXXXXX, XXXXX. Capricor Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Capricor Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCapricor Therapeutics Investment Activity
Capricor Therapeutics invested in XXX companies to date.
Capricor Therapeutics made its latest investment on XXXXXXXX, XXXXX. Capricor Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Capricor Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Capricor Therapeutics
| When was Capricor Therapeutics founded? | Capricor Therapeutics was founded in 2005. |
| Where is Capricor Therapeutics headquartered? | Capricor Therapeutics is headquartered in United States. |
| How many employees does Capricor Therapeutics have? | As of today, Capricor Therapeutics has over 160 employees. |
| Who is the CEO of Capricor Therapeutics? | Capricor Therapeutics' CEO is Linda Marban. |
| Is Capricor Therapeutics publicly listed? | Yes, Capricor Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Capricor Therapeutics? | Capricor Therapeutics trades under CAPR ticker. |
| When did Capricor Therapeutics go public? | Capricor Therapeutics went public in 2002. |
| Who are competitors of Capricor Therapeutics? | Capricor Therapeutics main competitors are Recursion Pharmaceuticals, Amylyx Pharmaceuticals, Pharma Mar, Hugel. |
| What is the current market cap of Capricor Therapeutics? | Capricor Therapeutics' current market cap is $2B. |
| What is the current revenue of Capricor Therapeutics? | Capricor Therapeutics' last 12 months revenue is $44M. |
| What is the current revenue growth of Capricor Therapeutics? | Capricor Therapeutics revenue growth (NTM/LTM) is 216%. |
| What is the current EV/Revenue multiple of Capricor Therapeutics? | Current revenue multiple of Capricor Therapeutics is 38.4x. |
| Is Capricor Therapeutics profitable? | No, Capricor Therapeutics is not profitable. |
| What is the current EBITDA of Capricor Therapeutics? | Capricor Therapeutics has negative EBITDA and is not profitable. |
| What is Capricor Therapeutics' EBITDA margin? | Capricor Therapeutics' last 12 months EBITDA margin is (256%). |
| What is the current EV/EBITDA multiple of Capricor Therapeutics? | Current EBITDA multiple of Capricor Therapeutics is (15.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.